Earnings
Precision BioSciences Plans Hepatitis B Cure Trial After Viral Marker Vanishes In Six Patients
The company selected a dose for mid-stage testing, with dosing expected in the first quarter of 2027.
DTIL
Precision BioSciences (DTIL) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
Precision BioSciences Prices $125 Million Offering At $7.75 A Share, Funding Two Gene-Editing Programs
The gene-editing company sold common stock and pre-funded warrants, with all of it coming from the company, at a 4.6% discount to the prior sale price.
SEC Filings
Precision BioSciences Cuts Quarterly Loss To $7.6 Million On A $12.7 Million Warrant Gain
A non-cash gain offset a $20.4 million operating loss, while stock sales now help support the company's runway-through-2028 claim.
SEC Filings
BlackRock Crosses 5% Of Precision Biosciences With A 1.38 Million-Share Stake
The asset manager reports 5.01% of the gene-editing company's common stock in a passive ownership filing.